NDRG2 and glioblastoma: Swellam et al. found that NDRG2 methylation in patients with GBM significantly increased with the deterioration of overall survival and progression-free survival, and that NDRG2 methylation levels can serve as an effective biomarker for diagnosis and prognosis [7].